Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot open-label study of tocilizumab in active Schnitzler's syndrome
2016-003828-23Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Schnitzler syndrome, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change in physician global assessment of total disease activity. Started Jan 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on 2016-003828-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003828-23.